How has the nature of chemotherapy and prostate cancer evolved? Janna Andrews, MD, explains that historically, there were not many options for patients who became resistant to androgen deprivation therapy beyond palliative care. However, upon completion of the TAX and SWOG trials in 2004, it was determined that Docetaxel was an effective therapy for improving metastatic castrate-resistant prostate cancer patient outcomes.
References:
N Engl J Med. 2004 Oct 7;351(15):1502-12.
Faculty and Financial Disclosures:
Dr. Andrews has no relevant financial disclosures.
